Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | I-BET151 | CTRPv2 | pan-cancer | AAC | -0.013 | 0.7 |
mRNA | BMS-536924 | GDSC1000 | pan-cancer | AAC | -0.014 | 0.7 |
mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.015 | 0.7 |
mRNA | Fumonisin B1 | CTRPv2 | pan-cancer | AAC | -0.016 | 0.7 |
mRNA | quizartinib | CTRPv2 | pan-cancer | AAC | 0.016 | 0.7 |
mRNA | ELCPK | CTRPv2 | pan-cancer | AAC | -0.021 | 0.7 |
mRNA | Bax channel blocker | CTRPv2 | pan-cancer | AAC | -0.016 | 0.7 |
mRNA | AR-42 | GDSC1000 | pan-cancer | AAC | 0.013 | 0.7 |
mRNA | LAQ824 | GDSC1000 | pan-cancer | AAC | 0.014 | 0.7 |
mRNA | KIN001-260 | GDSC1000 | pan-cancer | AAC | -0.013 | 0.7 |